Core Viewpoint - Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's subsidiary, Guangzhou Baiyunshan Tianxin Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the injection of Cefoperazone (0.5g, 1.0g), which has passed the consistency evaluation of quality and efficacy for generic drugs [1] Group 1 - The approved product, Cefoperazone injection, is a third-generation cephalosporin antibiotic [1] - Cefoperazone is indicated for the treatment of infections caused by sensitive microorganisms, including severe systemic infections, lower respiratory tract infections (including pneumonia), ear, nose, and throat infections, urinary tract infections, skin and soft tissue infections, bone and joint infections, gynecological infections, gastrointestinal, biliary, and abdominal infections, blood/peritoneal dialysis and continuous ambulatory peritoneal dialysis (CAPD)-related infections, central nervous system infections (including meningitis), and prevention of perioperative urinary tract infections [1]

Core Viewpoint - The company has received approval for its injectable Cefoperazone, indicating a significant advancement in its pharmaceutical offerings and potential market impact [1] Group 1 - The company, Guangzhou Baiyunshan Tianxin Pharmaceutical Co., Ltd., a subsidiary of Baiyunshan, has received the "Drug Supplement Application Approval Notice" from the National Medical Products Administration [1] - The injectable Cefoperazone (0.5g, 1.0g) has passed the consistency evaluation of quality and efficacy for generic drugs [1] - Cefoperazone is a third-generation cephalosporin antibiotic, suitable for treating infections caused by sensitive microorganisms [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內 容而引致的任何損失承擔任何責任。 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條而作出的。 茲刊載廣州白雲山醫藥集團股份有限公司（「本公司」）在上海證券交易所網站(www.sse.com.cn)刊登的 本公司關於子公司藥品通過仿製藥一致性評價的公告之中文全文，僅供參考。 廣州白雲山醫藥集團股份有限公司 董事會 中國廣州，2025年9月3日 药品通用名称：注射用头孢他啶 通知书编号：2025B04013、2025B04015 於本公告日，本公司董事會成員包括執行董事李小軍先生、程寧女士、程洪進先生、唐和平先生與 黎洪先生，及獨立非執行董事陳亞進先生、黃民先生、黃龍德先生與孫寶清女士。 证券代码：600332 证券简称：白云山 公告编号：2025-067 广州白云山医药集团股份有限公司 关于子公司药品通过仿制药一致性评价的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并 ...

证券代码：600332 证券简称：白云山 公告编号：2025-067 广州白云山医药集团股份有限公司 关于子公司药品通过仿制药一致性评价的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，广州白云山医药集团股份有限公司（以下简称"本公司"） 控股子公司广州白云山天心制药股份有限公司（以下简称"天心制药"） 收到国家药品监督管理局核准签发的《药品补充申请批准通知书》， 注射用头孢他啶（0.5g、1.0g）已通过仿制药质量和疗效一致性评价。 现将有关情况公告如下： 一、药品的基本情况 药品通用名称：注射用头孢他啶 通知书编号：2025B04013、2025B04015 受理号：CYHB2350966、CYHB2350965 剂型：注射剂 规格：0.5g（按C22H22N6O7S2计）、1.0g（按C22H22N6O7S2计） 注册分类：化学药品 药品注册标准编号：YBH22912025 原药品批准文号：国药准字H20010254、国药准字H19990365 二、药品的相关信息 天心制药于2002年9月取得注射用头孢他啶（ ...

Core Viewpoint - Recently, the company announced that its subsidiary, Guangzhou Baiyunshan Tianxin Pharmaceutical Co., Ltd., received approval from the National Medical Products Administration for the supplementary application of injectable Cefotaxime (0.5g, 1.0g), which has passed the consistency evaluation of quality and efficacy for generic drugs [1] Group 1 - The company has a significant development in its pharmaceutical segment with the approval of injectable Cefotaxime [1] - The approval indicates the company's commitment to enhancing its product portfolio and meeting regulatory standards [1] - This development may lead to increased market competitiveness for the company's pharmaceutical products [1]

Core Viewpoint - Baiyunshan (600332.SH) announced that its subsidiary, Guangzhou Baiyunshan Tianxin Pharmaceutical Co., Ltd., received approval from the National Medical Products Administration for the injection of Cefoperazone (0.5g, 1.0g), which has passed the consistency evaluation of generic drug quality and efficacy [1] Group 1 - The approved drug, Cefoperazone, is a third-generation cephalosporin antibiotic [1] - Cefoperazone is indicated for the treatment of infections caused by sensitive microorganisms, including severe systemic infections, lower respiratory tract infections (including pneumonia), ENT infections, urinary tract infections, skin and soft tissue infections, bone and joint infections, gynecological infections, gastrointestinal, biliary, and abdominal infections, blood/peritoneal dialysis, and central nervous system infections (including meningitis) [1] - The drug is also used for the prevention of perioperative urinary tract infections [1]

| 概念 | 今日涨跌幅（%） | 概念 | 今日涨跌幅（%） | | --- | --- | --- | --- | | 芬太尼 | 0.65 | 兵装重组概念 | -7.44 | | BC电池 | 0.39 | 国产航母 | -5.45 | | 青蒿素 | 0.17 | 军工信息化 | -4.97 | | 光刻胶 | 0.10 | 成飞概念 | -4.76 | | 重组蛋白 | 0.03 | 军民融合 | -4.67 | | 石墨电极 | 0.02 | 大飞机 | -4.10 | | HJT电池 | -0.23 | 中船系 | -4.07 | | 光刻机 | -0.25 | 航空发动机 | -3.87 | | 减肥药 | -0.27 | 商业航天 | -3.71 | | 创新药 | -0.43 | 卫星导航 | -3.59 | 资金面上看，今日青蒿素概念板块获主力资金净流出0.58亿元，其中，3股获主力资金净流入，净流入 资金居首的是百花医药，今日主力资金净流入1.09亿元，净流入资金居前的还有华润双鹤、浙江医药 等，主力资金分别净流入1416.28万元、579.44万元。 （原标题：青蒿素概念涨0.17 ...

Group 1 - Huazhong Securities has been approved to issue subordinate corporate bonds with a total face value of no more than 10 billion yuan [1] - Jinbei Automotive plans to invest 240 million yuan to establish an automotive industry investment fund focusing on electrification, intelligence, and low carbon [1] - Linyang Energy is expected to win a bid for a 244 million yuan metering equipment project from Southern Power Grid [1][2] Group 2 - Renfu Pharmaceutical's subsidiary has received drug registration certificates for two products, including a medication for acute hypotension [3][4] - Nanjing Steel plans to distribute a cash dividend of 0.1186 yuan per share [5][6] - Pairui Co. has signed a strategic cooperation agreement with Xi'an Power Electronics Research Institute to develop power devices [7][8] Group 3 - Haixing Electric is expected to win a bid for a 214 million yuan metering equipment project from Southern Power Grid [9][10] - Kuangda Technology is planning a change in control, leading to a continued suspension of its stock [11][12] - Samsung Medical is expected to win a bid for a 274 million yuan metering equipment project from Southern Power Grid [13][14] Group 4 - Jiukang Bio has obtained a medical device registration certificate for a specific diagnostic kit [15][16] - Hechuan Technology's minority shareholder plans to transfer a 13% stake in a subsidiary [17][18] - DiAo Micro has launched a new eUSB2 repeater product for various electronic applications [19][20] Group 5 - David Medical's electric surgical table registration application has been accepted [21][22] - Hangxin Technology plans to apply for a total of 280 million yuan in bank credit [23][24] - Liyuan Technology's non-independent director has resigned [25][26] Group 6 - Ningbo Construction's subsidiary has won a construction project bid worth 729 million yuan [27][28] - Huaren Pharmaceutical's subsidiary has received approval for a raw material drug [29][30] - Suwen Electric plans to distribute a cash dividend of 1 yuan per 10 shares [31][32] Group 7 - Solar Energy has received 1.692 billion yuan in renewable energy subsidies [33][34] - Wangli Security has obtained a patent for a new lock structure [35][36] - Zhejiang Energy's vice chairman has resigned due to age reasons [37][38] Group 8 - Beilu Pharmaceutical's subsidiary has passed GMP certification in Brazil [39][40] - Zhejiang Communications has a subsidiary that is expected to win a highway project bid [41][42] - Xinzhi Group has received a government subsidy of 11.1978 million yuan [43][44] Group 9 - Dong'an Power's engine sales in August increased by 3.44% year-on-year [45][46] - Baiyun Mountain's subsidiary has passed the consistency evaluation for two generic drugs [47][48] - Yipin Hong's subsidiary has received a drug registration certificate for a specific injection [49][50] Group 10 - Far East Holdings' subsidiary has won multiple contracts totaling 1.689 billion yuan [51][52] - Good Housekeeping's shareholder plans to reduce holdings by up to 3.5 million shares [53][54] - Guanghong Technology's shareholders have set a transfer price of 23.33 yuan per share [55][56] Group 11 - Keli Sensor plans to acquire 45% of Huahong Technology's shares for 122 million yuan [57][58] - Jianmin Group's furosemide oral solution has been approved for market launch [59][60] - Jinghua Laser's directors plan to reduce their holdings by up to 143,420 shares [61][62] Group 12 - Zhuyue Group is planning a share transfer that will change its controlling shareholder [63][64] - Terid has pre-bid for two projects totaling approximately 698 million yuan [65][66] - Zhonghuan Hailu is planning a change in control, leading to a continued suspension of its stock and convertible bonds [67][68] Group 13 - Great Wall Motors reported August sales of 115,600 vehicles, a year-on-year increase of 22.33% [69][70] - Guizhou Tire's controlling shareholder has committed not to reduce holdings for 12 months [71][72] - San Da Membrane's shareholder plans to reduce holdings by up to 1% of the company's shares [73][74] Group 14 - Chint Electric has decided to terminate the spin-off of its subsidiary for listing [75][76] - Jusaylong's shareholder plans to reduce holdings by up to 1% of the company's shares [77][78]

Group 1 - Baiyunshan's stock price increased by 0.45% on September 2, with a trading volume of 392 million yuan [1] - The financing buy-in amount for Baiyunshan on the same day was 52.78 million yuan, while the financing repayment was 75.43 million yuan, resulting in a net financing outflow of 22.65 million yuan [1] - As of September 2, the total financing and securities lending balance for Baiyunshan was 1 billion yuan, with the financing balance accounting for 2.65% of the circulating market value, indicating a high level compared to the past year [1] Group 2 - Baiyunshan's main business includes the research, development, manufacturing, and sales of traditional Chinese and Western medicines, chemical raw materials, and health products, with major revenue sources being large commercial (69.32%), health (16.79%), and traditional medicine (12.53%) [2] - For the first half of 2025, Baiyunshan reported a revenue of 41.835 billion yuan, a year-on-year increase of 1.93%, while the net profit attributable to shareholders was 2.516 billion yuan, a decrease of 1.31% year-on-year [2] Group 3 - Baiyunshan has distributed a total of 10.256 billion yuan in dividends since its A-share listing, with 3.708 billion yuan distributed in the last three years [3] - As of June 30, 2025, the top ten circulating shareholders of Baiyunshan included Hong Kong Central Clearing Limited and several ETFs, with notable changes in shareholding among these entities [3]

证券代码：600332 证券简称：白云山 公告编号：2025-066 （一）注射用头孢哌酮钠舒巴坦钠 药品通用名称：注射用头孢哌酮钠舒巴坦钠 通知书编号：2025B03888、2025B03891、2025B03893 受理号：CYHB2350978、CYHB2350964、CYHB2350979 广州白云山医药集团股份有限公司 关于子公司药品通过仿制药一致性评价的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 近日，广州白云山医药集团股份有限公司（以下简称"本公司"）控股子公司广州白云山天心制药股份有 限公司（以下简称"天心制药"）收到国家药品监督管理局核准签发的《药品补充申请批准通知书》，注 射用头孢哌酮钠舒巴坦钠（1.0g、1.5g、2.0g）、克林霉素磷酸酯注射液（2ml：0.3g、4ml：0.6g）已通 过仿制药质量和疗效一致性评价。现将有关情况公告如下： 一、药品的基本情况 剂型：注射剂 规格：1.0g（C25H27N9O8S2 0.5g与C8H11NO5S 0.5g）、1.5g（C25H27N9O8S2 1 ...